Robert Mittendorff II bought $20M of CARL
director at CARLSMED, INC.. 1,333,333 shares at an average of $15.00, traded Jul 24, 2025, filed Jul 24, 2025.
Score components
- +15RoleDirector
- +25Trade size$20.0M at market
- +6Relative to holdingsHoldings up 36%
- +10Price context0% above the 52-week low
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-098540, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 24, 2025 | CConversion Common Stockindirect: See footnotes | +3,680,506 | - | - | 3,680,506 | Jul 24, 2025 |
| Jul 24, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +1,333,333 | $15.00 | $20M | 5,013,839 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Common Stockindirect: See footnotes | +2,376,472 | - | - | 2,376,472 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Common Stockindirect: See footnotes | +931,452 | - | - | 931,452 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,445,020 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -2,235,486 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,445,020 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -931,452 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -931,452 | - | - | 0 | Jul 24, 2025 |
Related signals
Other insiders at CARLSMED, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CARLSMED, INC. | Jeffrey Bertolini Chief Operating Officer | $11k 747 shares | -3% | |
| 0Weak | CARLSMED, INC. | Jeffrey Bertolini Chief Operating Officer | $3,400 243 shares | -1% | |
| 65Notable | CARLSMED, INC. | Presidio Management Group XII, L.L.C. owner | $3.0M 200,000 shares | - | |
| 40Moderate | CARLsell CARLSMED, INC. | Michael Cordonnier CEO, President | $2.6M 197,855 shares | -13% | |
| 63Notable | CARLSMED, INC. | B Capital Group Management, L.p. owner | $20M 1,333,333 shares | +36% | |
| 74Notable | CARLSMED, INC. | Philip M Young director | $900k 59,999 shares | +208% | |
| 75Notable | CARLSMED, INC. | Jonathan D Root director | $7.0M 466,666 shares | +2692% | |
| 58Moderate | CARLSMED, INC. | Kevin Sidow director | $200k 13,333 shares | +29% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.